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1  | INTRODUC TION
Several lines of evidence suggest that central endogenous opioid 
peptides and receptors are involved in the regulation of salt in-
gestion. β- endorphin, comprising one of these, plays a key role in 
the modulation of salt hedonic palatability and sodium appetite, as 
well as in dietary- sodium- overload induced sympathetic and pres-
sor responses.1-5 Previous results from our laboratory indicated 
that β- endorphin knockout mice and heterozygous mutant mice 
consume approximately 50% less 2% NaCl solution than wild- 
type mice after sodium depletion, suggesting that β- endorphin 
facilitates induced sodium appetite.3 On the other hand, our re-
sults also showed that endogenous β- endorphin is implicated in 
the compensatory response to body sodium overload.6,7 This was 
demonstrated by β- endorphin knockout mice displaying increased 
systolic blood pressure, urinary epinephrine excretion and me-
dian preoptic nucleus (MnPO) neural activity (as shown by Fos- 
immunoreactivity), when submitted to a high- sodium diet (4% 
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Numerous studies demonstrate the significant role of central β- endorphin and its 
receptor, the μ- opioid receptor (MOR), in sodium intake regulation. The present study 
aimed to investigate the possible relationship between chronic high- NaCl intake and 
brain endogenous MOR functioning. We examined whether short- term (4 days) ob-
ligatory	salt	intake	(2%	NaCl	solution)	in	rats	induces	changes	in	MOR	mRNA	expres-
sion, G- protein activity and MOR binding capacity in brain regions involved in salt 
intake regulation. Plasma osmolality and electrolyte concentrations after sodium 
overload and the initial and final body weight of the animals were also examined. 
After	4	days	of	obligatory	hypertonic	sodium	chloride	 intake,	 there	was	clearly	no	
difference	in	MOR	mRNA	expression	and	G-	protein	activity	in	the	median	preoptic	
nucleus (MnPO). In the brainstem, MOR binding capacity also remained unaltered, 
although the maximal efficacy of MOR G- protein significantly increased. Finally, no 
significant alterations were observed in plasma osmolality and electrolyte concentra-
tions. Interestingly, animals that received sodium gained significantly less weight 
than control animals. In conclusion, we found no significant alterations in the MnPO 
and brainstem in the number of available cell surface MORs or de novo syntheses of 
MOR after hypertonic sodium intake. The increased MOR G- protein activity follow-
ing acute sodium overconsumption may participate in the maintenance of normal 
blood pressure levels and/or in enhancing sodium taste aversion and sodium 
overload- induced anorexia.
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NaCl) for 2 weeks, whereas no effect was registered in wild- type 
and	 heterozygous	 mice.	 Additionally,	 Caeiro	 and	 Vivas	 (2008)7 
showed that β- endorphin- MnPO administration produces a de-
crease in blood pressure and heart rate in normotensive animals 
and inhibits the pressor response evoked by an acute increase in 
plasma osmolality.
Numerous studies demonstrate the significant role of the μ- 
opioid receptor (MOR) in sodium intake regulation. The MOR, to-
gether with two other classical types of opioid receptors, κ and δ, 
belongs	to	the	G-	protein	coupled	receptor	(GPCR)	superfamily.	All	
of these receptors predominantly couple to Gαi/o type inhibitory 
G- proteins,8 which inhibits adenylyl cyclase activity,9 decreases cal-
cium ion entry10 and increases potassium ion efflux.11 It has been 
demonstrated that central injection of the selective MOR agonist 
[d-	Ala2,N-	MePhe4,Gly5-	ol]-	enkephalin	 (DAGO)	 significantly	 in-
creased the intake of saline solution (at both 0.6% and 1.7% NaCl) 
in nondeprived rats.12 Moreover, systemic injection of morphine in-
creased the preference of mice and rats for normally aversive hyper-
tonic NaCl solutions (1.5%- 30% NaCl).13,14 Increased MOR signalling 
along the nucleus accumbens, ventral pallidum and central amygdala 
nucleus	 (CeA)	has	been	mainly	associated	with	 the	hedonic	palat-
ability of NaCl when it is tasted.5,15-17 MOR activity along the brain-
stem,	within	the	lateral	parabrachial	nucleus	(LPBN)	and	the	nucleus	
of the solitary tract (NTS), mainly modulates motivated sodium/food 
intake and blood pressure.18-21
However, experiments such as these fail to determine the 
mechanisms by which endogenous MOR signalling acts to modu-
late sodium appetite and blood pressure regulation. The present 
study aimed to investigate the effect of increased salt intake (2% 
NaCl solution) in rats during a short period of time (4 days) on 
MOR	mRNA	expression	along	 the	MnPO	and	 the	NTS.	We	also	
explored brainstem and MnPO MOR G- protein activity (efficacy 
and potency), well as brainstem MOR binding capacity, to deter-
mine whether sodium overload induced any changes in the sig-
nalling and binding properties of the MOR in these brain regions. 
Finally, we also examined the changes in plasma concentrations 
of Na+, K+ and Cl− and body weight of the animals after the so-
dium overload.
2  | MATERIAL S AND METHODS
2.1 | Chemicals
Tris-	HCl,	ethylene	glycol	tetraacetic	acid	(EGTA),	NaCl,	MgCl2 × 6H2O, 
GDP and the GTP analogue GTPγS	were	purchased	from	Sigma-	Aldrich	
(Budapest,	 Hungary).	 The	 highly	 selective	 MOR	 agonist	 enkepha-
lin analog, Tyr- d-	Ala-	Gly-	(NMe)Phe-	Gly-	ol	 (DAMGO),	 was	 obtained	
from	Bachem	Holding	AG	(Bubendorf,	Switzerland).	The	nonselective	
opioid receptor antagonist, naloxone, was kindly provided by Endo 
Laboratories	of	DuPont	de	Nemours	(Wilmington,	DE,	USA).	Ligands	
were	dissolved	in	water	and	were	stored	in	1	mmol	L-1 stock solution 
at	 −20°C.	 The	 radiolabelled	 GTP	 analogue	 [35S]GTPγS (specific ac-
tivity: 1250 Ci mmol-1)	 was	 purchased	 from	 PerkinElmer	 (Budapest,	
Hungary). [3H]DAMGO	 (specific	 activity:	 38.8	Ci	mmol-1) was radi-
olabelled	in	the	Isotope	Laboratory	of	BRC	(Szeged,	Hungary)	and	has	
been characterised previously.22	The	Ultima	Gold	MV	aqueous	scintil-
lation	cocktail	was	purchased	from	PerkinElmer	(Budapest,	Hungary).
2.2 | Animals
As	 a	 result	 of	 collaboration,	 we	 used	 two	 rat	 strains	 provided	 by	
each local research institute. Male, Wistar- derived rats (350- 400 g) 
from the colony of the Instituto de Investigación Médica Mercedes 
y Martin Ferreyra (INIMEC- CONICET, Universidad Nacional de 
Córdoba,	 Córdoba,	 Argentina)	 were	 used	 for	 the	 relative	 MOR	
mRNA	 expression	 and	 plasma	 osmolality	 and	 electrolyte	 analysis.	
The MOR binding experiments were carried out in male Sprague- 
Dawley rats (200- 300 g) obtained from the animal house of the 
Department	 of	 Pharmacodynamics	 and	 Biopharmacy,	 Faculty	 of	
Pharmacy, University of Szeged (Szeged, Hungary).
Animals	 were	 kept	 under	 a	 12:12	hour	 light/dark	 cycle,	 in	 a	
temperature- controlled environment, with food and water avail-
able ad libitum until the initiation of the experiments. Each animal 
was	 used	 in	 only	 one	 experimental	 condition.	 All	 of	 the	 experi-
mental protocols in Wistar rats were approved and carried out in 
accordance with the guidelines of the Ferreyra Institute Ethical 
Committee for the use and care of laboratory animals, as well as 
the guidelines of the International Public Health Service Guide for 
the	Care	and	Use	of	Laboratory	Animals.	Housing	and	experiments	
performed in Sprague- Dawley rats were in accordance with the 
European Communities Council Directives (2010/63/EU) and the 
Hungarian	Act	for	the	Protection	of	Animals	in	Research	(XXVIII.
tv.	 32.§,	 registration	 number:	 IV./141/2013.).	 All	 efforts	 were	
made to minimise animal suffering and to reduce the number of 
animals used.
2.3 | Experimental design
As	indicated	in	Figure	1,	the	experimental	group	had	access	only	to	
2% NaCl solution (2% NaCl), whereas the control group (CON) had 
ad libitum access to deionised water during the 4- day protocol pe-
riod, after which the animals were used for the appropriate experi-
mental	set-	up.	Both	experimental	and	control	groups	had	normal	
access to commercial diet. Plasma was collected from both groups 
(CON and 2% NaCl) at the end of the treatment to measure plasma 
osmolality	and	electrolyte	concentrations.	Body	weight	was	meas-
ured in both groups at the beginning and at the end of the protocol.
2.4 | Relative mRNA expression of MOR (Oprm1)
2.4.1 | Brain microdissection, tissue collection, RNA 
extraction and calibration of primers
After	4	days	of	control	or	sodium	overload	conditions,	the	animals	
were decapitated and brains immediately excised and stored at 
−80°C	for	mRNA	determination.	Coronal	sections	of	540	μm in the 
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MnPO and of 780 μm in the nucleus of the solitary tract (NTS) were 
obtained from the frozen brains in a microtome with a stainless- steel 
punch needle. The brain nuclei were identified and delimited in ac-
cordance with a rat brain atlas.23	The	mRNA	was	isolated	from	mi-
cropunches of specific brain areas, using TRIzol reagent (Invitrogen, 
Carlsbad,	CA,	USA)	in	accordance	with	the	manufacturer’s	instruc-
tions	 with	 some	 modifications:	 RNA	 precipitation	 with	 isopro-
panol	 was	 performed	 overnight	 at	 −20°C.	 The	 RNA	 was	 treated	
with	 DNase	 (Fermentas,	 Glen	 Burnie,	 MD,	 USA)	 and	 quantified	
using	 a	 NanoDrop	 2000	 UV-	Vis	 Spectrophotometer	 (NanoDrop,	
Wilmington,	DE,	USA)	and	then	reverse-	transcribed	into	cDNA	(en-
zyme	RTM-	MLV)	(Promega,	Madison,	WI,	USA).
Brain	Oprm1 gene expression was determined using Syber Green 
Real-	Time	PCR	Master	Mixes	(Applied	Biosystems,	Foster	City,	CA,	
USA)	 in	 the	 Step	One	Real-	Time	 equipment	 (Applied	Biosystems).	
PCR amplification efficiency was established by means of 5- point 
1:10 calibration curves. The selected dilution for the samples was 
1:10 from the initial RT PCR concentration. The Ct values of the 
samples fell into the linear dynamic range of the calibration curve. 
All	primer-	pairs	were	confirmed	to	be	90%-	110%	efficient	by	means	
of the calibration curve, with efficiencies E = 2 ± 0.1 (E = 10[−1/slope]) 
and amplified a single product determined by melting curve analysis. 
The	primer	sequences	are	provided	in	Table	1.
2.4.2 | Calculations of relative gene expression
The	 relative	 quantification	 was	 determined	 by	 the	 ΔΔCt method 
with stepone, version 2.2 (Thermo Fisher Scientific Inc., Waltham, 
MA,	USA),	where	the	fold	change	of	mRNA	content	in	the	unknown	
sample relative to control group was determined by calculating a 
ratio = (Etarget)ΔCt(target)/(EGapdh)ΔCt(Gapdh), where E is the efficiency of 
the primer set and ΔCt = Ct(control)−Ct(experimental). For each sample, 
the Ct was determined and normalised to the average of the house-
keeping gene, Gapdh.	 Relative	 quantifications	 of	 the	 target	 gene	
(Oprm1) were normalised to each control group. Data are presented 
as	mRNA	 expression	 relative	 to	 the	 control	 calibrator	 group.	 The	
2−ΔCT method was used to determine the expression of Gapdh be-
tween treatments (CON vs NaCl 2%). The relative amounts of Gapdh 
were calculated using the 2−ΔCT	equation,	where	ΔCT = CT treated 
- CT control.24
2.5 | Receptor binding assays
2.5.1 | Preparation of brain samples for 
binding assays
After	 the	 final	day	of	 treatment,	12	 rats	 for	 the	experimental	 and	
control	 conditions	were	decapitated	and	 their	brains	were	quickly	
removed. The brainstems were prepared for membrane preparation 
as	described	by	Benyhe	et	al.25 and partly used for saturation binding 
experiments and partly further prepared for the [35S]GTPγS binding 
protocols, as described by Zádor et al.26 The brainstem and MnPO 
were separated in accordance with the rat brain atlas of Paxinos and 
Watson23	and	were	homogenised	and	suspended	in	Tris-	HCl,	EGTA	
and MgCl2 buffer for [
35S]GTPγS binding assays.
2.5.2 | Functional [35S]GTPγS binding experiments
The functional [35S]GTPγS binding experiments were performed 
as described previously,27,28	 with	 modifications.	 Briefly,	 the	
F IGURE  1 Schematic diagram showing 
the experimental design and protocols
Day 1 Day 5
Body weight was measured at the 
beginning and at the end of the protocol
Control group
(CON)
ad libitum access to
deionised water
and commercial diet
Experimental group
(2%NaCl)
access only to 
2% NaCl solution and
commercial diet
Male adult rats
(Wistar/Sprague-Dawley)
4 days of control/sodium overload conditions
Euthanasia - brain removal 
(Relative mRNA expression/
Receptor binding assays)
Plasma collection
Oprm1 Gapdh
GenBank	access	number NM_001304737.1 NM_017008.4 
Primer	forward	5′-	to	3′ CTGTCTGCCACCCAGTCAAA TGTGAACGGATTTGGCCGTA
Primer	reverse	5′-	to	3′ TGCAATCTATGGACCCCTGC ATGAAGGGGTCGTTGATGGC
Product size (bp) 150 93
Annealing	temperature	(°C) 60°C 59°C
TABLE  1 Primer pairs for Oprm1 and 
Gapdh	mRNAs
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membrane fractions of brainstem and MnPO homogenates were 
incubated	 at	 30°C	 for	 60	minutes	 in	 Tris-	EGTA	buffer	 (pH	7.4)	
comprising	 50	mmol	L-1	 Tris-	HCl,	 1	mmol	L-1	 EGTA,	 3	mmol	L-1 
MgCl2	and	100	mmol	L
-1	NaCl,	containing	20	MBq/0.05	cm3 [35S]
GTPγS	 (0.05	nmol	L-1) and increasing concentrations (10−10 to 
10−5	mol	L-1)	of	DAMGO.	The	experiments	were	performed	in	the	
presence of excess GDP (30 μmol	L-1)	 in	 a	 final	 volume	of	 1	mL.	
Total binding was measured in the absence of test compounds, 
determining nonspecific binding in the presence of 10 μmol	L-1 
unlabelled GTPγS. The difference represents basal activity. The 
reaction was terminated by rapid filtration under vacuum (M24R 
Cell	 Harvester;	 Brandel,	 Boca	 Raton,	 FL,	 USA)	 and	 washed	
three	 times	with	 5	mL	 of	 ice-	cold	 50	mmol	L-1 Tris- HCl (pH 7.4) 
buffer	through	Whatman	GF/B	glass	fibres	(GE	Healthcare,	Little	
Chalfont, UK). The radioactivity of the dried filters was detected 
in	an	UltimaGold	MV	aqueous	scintillation	cocktail	(Perkin	Elmer,	
Waltham,	 MA,	 USA)	 with	 a	 Tricarb2300TR	 liquid	 scintillation	
counter	(Packard,	Palo	Alto,	CA,	USA).	[35S]GTPγS binding experi-
ments were performed in triplicate and repeated at least three 
times.
2.5.3 | Saturation binding experiments
Aliquots	 of	 frozen	 rat	 brainstem	 membrane	 homogenates	 were	
centrifuged	 (36288	 g	 for	 20	minutes	 at	 4°C)	 to	 remove	 sucrose	
and	the	pellets	were	suspended	in	50	mmol	L-1 Tris- HCl buffer (pH 
7.4). Membranes were incubated in the presence of [3H]DAMGO	
in	 increasing	 concentrations	 (1.06	 to	 24.32	nmol	L-1)	 at	 35°C	 for	
45	minutes.	Both	nonspecific	 and	 total	 binding	were	determined	
in the presence and absence of 10 μmol	L-1 unlabelled naloxone, 
respectively. The reaction was terminated by rapid filtration under 
vacuum	(M24R	Cell	Harvester)	and	washed	three	times	with	5	mL	
of	ice-	cold	50	mmol	L-1 Tris- HCl (pH 7.4) buffer through Whatman 
GF/C glass fibres. The radioactivity of the dried filters was de-
tected	 in	an	UltimaGold	MV	aqueous	scintillation	cocktail	with	a	
Tricarb	2300TR	liquid	scintillation	counter.	The	saturation	binding	
assays were performed in duplicate and repeated at least three 
times.
2.6 | Plasma osmolality and electrolyte analysis
For the assay of plasma osmolality and electrolyte concentrations, 
we used groups of animals different from those used in the relative 
mRNA	expression	 and	 receptor	binding	 studies.	 The	 animals	 from	
both groups (CON and 2% NaCl) were decapitated and bled at the 
end of the 4 days of treatment. Trunk blood was collected in chilled 
tubes containing ethylenediaminetetraacetic acid (final concentra-
tion	 2	mg	mL-1 blood) for centrifugation at 1008 g for 10 minutes 
at	 4°C.	 Plasma	 electrolyte	 concentrations	 were	 measured	 with	 a	
Beckman	Lablyte	system	 (model	810;	Beckman	 Instruments,	Brea,	
CA,	USA),	 plasma	 osmolality	was	 determined	 from	 duplicate	 8-	μL	
plasma	 samples	 using	 vapor	 pressure	 osmometry	 (VAPRO	 5520;	
Wescor	Inc.,	Logan,	UT,	USA).
2.7 | Statistical analysis
2.7.1 | Relative mRNA expression of MOR 
(Oprm1), plasma osmolality, weight and electrolyte 
concentration data
Relative	 mRNA	 expression	 of	 MOR	 (Oprm1), plasma osmolality, 
weight and electrolyte concentration data were subjected to a t test, 
and the loci of significant effects were further analysed using a one- 
way	ANOVA	Tukey’s	test	(type	I	error	probability	was	set	at	.05).	All	
experimental data are presented as the mean ± SEM.
2.7.2 | Receptor binding data
The specific binding of the radiolabelled compounds ([35S]GTPγS, 
[3H]DAMGO)	was	calculated	by	subtracting	the	nonspecific	binding	
values from total binding values and expressed as a percentage. Data 
were normalised to total specific binding, which was set at 100%, 
which, in the case of [35S]GTPγS binding assays, also represents the 
level of G- protein basal activity. Experimental data are presented as 
the mean ± SEM as a function of the applied ligand concentration 
range, which, in the case of [35S]GTPγS binding assays, was indi-
cated in logarithm form. Points were fitted with prism, version 5.0 
(GraphPad	Prism	Software	Inc.,	San	Diego,	CA,	USA),	using	nonlin-
ear regression. In the [35S]GTPγS binding assays, the ‘Sigmoid dose- 
response’	 fitting	was	used	 to	establish	 the	maximal	 stimulation	or	
efficacy (Emax) of the G- protein coupled receptors and the ligand 
potency (EC50). Stimulation was given as a percentage of the specific 
[35S]GTPγS binding observed over basal activity, which was set at 
100%.	In	saturation	binding	assays,	the	‘one	site	-	specific	binding’	
fitting	 equation	was	 applied	 to	 establish	 the	 concentration	 of	 the	
radioligand that produced 50% of the maximal binding capacity or, in 
other words, the dissociation constant (Kd) and the maximum binding 
capacity of the receptor (Bmax). The amount of receptors that spe-
cifically bound [3H]DAMGO	is	presented	in	fmol	mg-1, as calculated 
by the total protein content and the amount of radioligand in the 
appropriate concentration point, as well as by the specific activity 
of	the	radioligand.	An	unpaired	t test with a two- tailed P value was 
performed to determine the significance level, using prism, version 
5.0. P < .05 level was considered statistically significant.
3  | RESULTS
3.1 | Relative gene expression of the MOR (Oprm1)
After	 treatments	 (CON	 and	 2%	 NaCl),	 no	 significant	 differences	
were observed in the relative gene expression of the μ- opioid recep-
tor (Oprm1) in any of the brain nuclei analysed (Figure 2).
3.2 | MOR G- protein activity measurements
To test the effect of high sodium intake treatment on MOR activity 
(efficacy and potency), we performed functional [35S]GTPγS binding 
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assays.	This	type	of	assay	can	monitor	the	GDP→GTP	exchange	of	
the Gαi/o protein with the radioactive, nonhydrolysable GTP ana-
logue [35S]GTPγS during agonist- mediated receptor activation. The 
MOR was stimulated with increasing concentrations of the highly 
MOR-	selective	pure	agonist	peptide	DAMGO.	The	assays	were	per-
formed in control and experimental groups of rat brainstem mem-
brane homogenate and in MnPO homogenates.
In the control group brainstem membrane homogenates, the ag-
onist	DAMGO	increased	the	specific	binding	of	[35S]GTPγS in MOR 
Gi/o protein in a concentration- dependent manner. The increased 
specifically bound [35S]GTPγ S reached a 32% maximum over basal 
activity (100%), thus demonstrating a total of 132 ± 2.6% maxi-
mum efficacy (Emax)	 for	 the	MOR	G-	protein,	with	 a	238.1	nmol	L
-1 
(pEC50:	 6.62	±	0.2	mol	L
-1) potency (EC50)	 of	 the	 agonist	 DAMGO	
(Figure	3A).	 The	 2%	 sodium	 intake	 significantly	 enhanced	 MOR	
agonist- mediated maximum G- protein efficacy (143.7 ± 2.3%) 
(Figure	3A),	 whereas	 the	 potency	 of	 DAMGO	 remained	 unaltered	
(pEC50:	6.81	±	0.13	mol	L
-1)	(Figure	3A).
In	the	MnPO	homogenates,	DAMGO	activated	MORs	G-	protein	
over the basal activity more effectively than in the brainstem because 
the activation resulted in 168.6 ± 3.6% MOR maximum efficacy, 
which	is	approximately	30%	more	than	in	the	brainstem	(Figure	3B).	
In	the	MnPO,	the	potency	of	DAMGO	was	slightly	lower	than	in	the	
brainstem,	at	271.4	nmol	L-1 (pEC50:	6.56	±	0.12	mol	L
-1)	(Figure	3B).	
However, 2% sodium chloride consumption did not cause signifi-
cant	changes	either	in	G-	protein	efficacy	(163.5	±	5.7%)	(Figure	3B)	
or agonist potency (pEC50:	6.41	±	0.2	mol	L
-1)	(Figure	3B).
3.3 | MOR binding capacity measurements
In the next step, we investigated the correlation of the enhanced 
G- protein activity of MOR and the higher levels of available MORs 
in the brainstem after chronic sodium exposure. We performed 
saturation binding experiments, in which we saturated MORs with 
increasing concentrations of [3H]DAMGO.	Thus,	we	could	calculate	
the maximal binding capacity (Bmax) of the MOR and the dissocia-
tion constant (Kd, binding affinity) of [
3H]DAMGO	after	normal	so-
dium or high sodium intake in brainstem membrane homogenates. 
The high sodium intake treatment did not change the maximal bind-
ing capacity of the MOR (96.2 ± 7.9 fmol g-1 vs 86.3 ± 5.5 fmol g-1) 
(Figure 3) or the Kd value of the [
3H]DAMGO	 (5.3	±	1	nmol	L-1 vs 
5	±	0.8	nmol	L-1) (Figure 4).
3.4 | Plasma osmolality, electrolyte and body 
weight analysis
No differences were observed in plasma osmolality and plasma elec-
trolyte concentrations in control and experimental groups (Table 2). 
However, the 4 days of 2% NaCl ingestion reduced weight gains in 
both Wistar and Sprague- Dawley rats compared to their respective 
control groups (Table 3).
4  | DISCUSSION
Based	on	previous	data	demonstrating	the	importance	of	MOR	sig-
nalling in body sodium homeostatic responses, the present study 
aimed to investigate whether increased salt intake in rats may induce 
changes	 in	 MOR	 mRNA	 expression,	 G-	protein	 activity	 and	 MOR	
binding capacity in brain regions previously involved in salt intake 
and	blood	pressure	regulation.	Although,	after	4	days	of	obligatory	
hypertonic sodium chloride intake, there was no difference in the 
binding properties of the MOR system, there were clearly evident 
changes in the maximal efficacy of MORs G- protein, increasing the 
receptor activity for signalling within the brainstem.
Our results also showed that, at least along the MnPO and at 
brainstem	 level,	 MOR	 binding	 capacity	 and	 mRNA	 receptor	 ex-
pression did not change and thus did not explain the β- endorphin 
modulation after sodium loading conditions. If we hypothesise 
that more receptors are available on the surface membrane along 
the brainstem, then more G- proteins could couple to them, thus 
increasing their maximum efficacy. However, our saturation bind-
ing experiments exclude this hypothesis: the MORs were sat-
urated	 to	 an	 almost	 equal	 level	 in	 the	 control	 and	 experimental	
groups in this brain region, indicating no alteration in the number 
of available MORs on the cell surface. This was confirmed by our 
G- protein activity measurements, in which the control and exper-
imental brain samples had similar radioactivity values of specif-
ically bound [35S]GTPγS (data not shown). We can also rule out 
the possibility of improved binding capacities of MORs after the 
high salt intake because neither the potency, nor the dissociation 
constant was altered in the brainstem, comprising parameters that 
describe	the	binding	properties	of	DAMGO	and	[3H]DAMGO,	re-
spectively. The most likely explanation of our results is that the 
amount of Gi/o- protein available for coupling was increased after 
F IGURE  2 Relative	mRNA	expression	
of opioid receptor Mu1 (Opr1)	at	the	(A)	
median	preoptic	nucleus	(MnPO)	and	(B)	
nucleus	of	the	solitary	tract	(NTS).	Bar	
graphs show relative Mu1	mRNA	gene	
expression in control (CON) (open bars) 
and sodium overload (filled bars) rats. 
Values	are	the	mean	±	SEM	(n	=	3-	4	per	
group) CON 2% NaCl
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4 days of hypertonic sodium intake, perhaps activating this sys-
tem and counterbalancing the sodium- overload increase in sympa-
thetic activity and blood pressure and provoking the well- known 
sodium overload- induced anorexia.
Sodium ion has long been known to inhibit opioid agonist binding 
at	near	physiological	concentrations	(100–140	mmol	L-1) in vitro,29,30 
and, moreover, a distinct binding pocket on the MOR has recently 
been described for the ion.31 It has also been demonstrated that 
lower sodium concentrations increased basal G- protein coupling, 
which	 reduced	 the	 DAMGO-	mediated	 MOR	 G-	protein	 maximum	
stimulation.32 The sodium ion can also promote the activation of 
the MOR by enhancing the movement of water molecules toward 
the allosteric site, as indicated by molecular dynamics simulations.33 
Although	there	were	no	differences	in	plasma	sodium	concentration	
between control and experimental groups when monitored after 
4 days of 2% NaCl ingestion, sodium concentrations may change 
during the 4- day study, contributing to the enhancement of G- 
protein activity. Thus, a “sodium effect” on MOR binding and signal-
ling cannot be entirely excluded.
Another	interesting	observation	of	this	model	was	that,	despite	
the plasma sodium concentration and osmolality remaining at the 
physiological level, reflecting the different types of efficient renal 
compensatory mechanisms, the body weight of animals after 4 days 
of 2% NaCl ingestion was significantly lower than that of the control 
group (Table 3). This may reflect a loss of body fluid stimulated by 
renal mechanisms that attempt to compensate for the high plasma 
sodium concentration, and particularly the natriuresis- driven di-
uretic water loss mechanism. On the other hand, our preliminary 
food intake data (not shown) indicate that there is a comparatively 
reduced food intake in sodium overload animals, which may also ex-
plain their body weight loss. However, another mechanism triggered 
by dietary high salt intake during long- term studies (100- 200 days) 
has been described recently.34 In this case, high salt intake may 
reprioritise osmolality and energy metabolism for body fluid con-
servation (mainly by urea production by liver and skeletal muscle), 
which provokes a reduction in body weight. This stage may be still 
not reached in our short- term study.
The brainstem pathways leading to the perception of salt in-
volve	a	circuitry	in	which	the	NTS	and	LPBN	are	the	key	sites	that	
receive and integrate both homeostatic salt and satiety signals. The 
LPBN,	for	example,	receives	direct	inputs	from	central	osmo-	sodium	
receptors located in the sensory circumventricular organs of the 
F IGURE  3 μ-	opioid	receptor	G-	protein	activity	in	DAMGO-	stimulated	[35S]GTPγS	binding	assays	in	rat	(A)	brainstem	membrane	and	(B)	
median preoptic nucleus (MnPO) homogenates during sodium overload. Specifically bound [35S]GTPγS is indicated as a percentage in the 
presence of increasing concentrations (1010 to 10−5	mol	L-1)	of	DAMGO	in	control	(CON)	and	after	2%	NaCl	treatment	in	rats	in	the	indicated	
brain areas.*Significant alteration in Emax value after treatment (unpaired t test, two- tailed P value). Points and columns represent the 
mean ± SEM for at least three experiments performed in triplicate. μ- Opioid receptor (MOR) basal activity was set as 100%. *P < .01
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TABLE  2 Plasma osmolality and electrolyte concentrations after 
4 days of sodium overload
CON 2% NaCl
OSM (mOsm kg-1 H2O) 309 ± 1.97 314.14 ± 4.27
Na+	(mEq	L-1) 140.12 ± 1.08 140.88 ± 1.35
K+	(mEq	L-1) 8.03 ± 0.11 9.06 ± 0.31
Cl−	(mEq	L-1) 99.90 ± 2.32 99.76 ± 2.27
Data are the mean ± SEM.
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lamina terminalis, and indirect inputs from peripheral osmorecep-
tors through the vagus nerve.35 Many neurotransmitters/neuro-
modulators	 regulate	 its	 responses	 (serotonin,	 angiotensin,	GABA,	
noradrenaline) and opioid signalling has been shown to modulate 
salt appetite.20,21,36	 The	 LPBN	 contains	 neurones	 that	 express	
enkephalins and MORs37 and pharmacological activation of MOR 
within this nucleus increases salt consumption.20,21	A	second	major	
pathway within the brainstem by which the brain detects body 
sodium status is via neurones residing in the dorsocaudal subre-
gion of the NTS that has fenestrated capillaries and expresses 11β- 
hydroxysteroid dehydrogenase type 2.38 This nucleus contains the 
second- order salt- sensitive neurones that receive gustatory infor-
mation coming from the first- order sensory neurones within the 
lingual branch of the glossopharyngeal nerve, the superficial pe-
trosal branch of the facial nerve and the laryngeal branch of the 
vagus nerve.39 In addition to receiving gustatory information about 
salt, it is important to take into account that a bi- directional opioid- 
opioid signalling pathway exists between the rostral NTS and the 
CeA,	which	 influences	 appetitive	 behaviours	 such	 as	 food	 intake	
via MORs.40	A	similar	opioid	circuitry	exists	within	the	LPBN	that	
projects	 to	 the	CeA,	which	 then	activates	 the	mesolimbic	 reward	
system involved in the motivation to consume salt and its rewarding 
palatability.5,17,41
In conclusion, the results of the present study have revealed 
that acute sodium overconsumption increases the maximal efficacy 
of MORs G- protein, increasing the receptor activity for signalling 
within the brainstem. This probably reflects the influence of the 
endogenous brainstem μ- opioid receptor system with respect to 
regulating the maintenance of normal blood pressure levels and/or 
enhancing sodium taste aversion and sodium overload- induced an-
orexia in response to central and visceral homeostatic inputs. For 
further studies, it would be interesting to examine whether the en-
hanced MOR G- protein activity further affects Gi/o- mediated sig-
nalling, such as adenylate cyclase activity.
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